Powerup Acquisition CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Aspire Biopharma Holdings, Inc. has finalized the acquisition of Dura Driver Control Systems (DCS) for approximately $30.0 million in cash, funded by a new $22.5 million revolving credit facility and cash on hand, marking a significant diversification into the automotive sector.
Aspire Biopharma Holdings, Inc. issued a Form 8-K to clarify the terms of its public warrants (ASPBW) following significant reverse stock splits.
Aspire Biopharma Holdings, Inc. has adjourned its shareholder meeting to June 16, 2026, due to a failure to reach a quorum.
Aspire Biopharma Holdings, Inc. has entered into a definitive agreement to acquire Dura Driver Control Systems for $30 million in cash.
Aspire Biopharma Holdings, Inc. has filed a Form 8-K announcing a 1-for-30 reverse stock split of its common stock, effective May 11, 2026.
Aspire Biopharma Holdings, Inc. announced the closing of its $21 million private placement and a commitment letter for a $22.5 million credit facility to fund the acquisition of Dura Control Systems.
Aspire Biopharma Holdings, Inc. has successfully closed the second tranche of its Series A Convertible Preferred Stock offering, raising $10 million in gross proceeds.
Aspire Biopharma Holdings, Inc. closed a $10 million private placement of Series A Convertible Preferred Stock to bolster equity and maintain Nasdaq listing compliance.
Aspire Biopharma Holdings stockholders approved a reverse stock split, increased authorized shares, and equity issuance proposals.
Aspire Biopharma Holdings has signed a letter of intent to acquire automotive supplier Dura Driver Control Systems for $30 million in cash.
Aspire Biopharma Holdings, Inc. has entered into a non-binding letter of intent to acquire the Driver Controls Systems business unit of Firefish Topco, LLC for $30 million.
Aspire Biopharma Holdings, Inc. announced a private placement of up to $21 million in convertible preferred stock, strengthening its balance sheet and aiming for Nasdaq listing compliance.
Aspire Biopharma Holdings, Inc. has designated 25,000 shares of Series A Convertible Preferred Stock, outlining conversion rights, ranking, and other preferences.
Aspire Biopharma Holdings, Inc. has entered into a Securities Purchase Agreement to raise $2 million through the sale of debentures with an 8% original issue discount and 790,000 incentive shares.
Aspire Biopharma Holdings, Inc. announced the Board's confirmation of the 2024 Stock Incentive Plan's share limits and approval of equity award agreements, aiming to attract and retain key talent.
Aspire Biopharma Holdings, Inc. announced the immediate resignation of Director Surendra Ajjarapu, effective January 7, 2026, with no reported disagreements.
Aspire Biopharma Holdings, Inc. entered into agreements to exchange approximately $1.75 million in debt for common stock with certain holders, aiming to strengthen its balance sheet.
Aspire Biopharma Holdings, Inc. entered into a new Equity Line of Credit agreement for up to $100 million, replacing a prior facility, to fund general corporate purposes.
Aspire Biopharma Holdings' stockholders approved a potential reverse stock split and the issuance of shares for convertible promissory notes at a special meeting.
Aspire Biopharma Holdings, Inc. received a delisting notice from Nasdaq for failing to meet minimum market value and bid price requirements.
Aspire BioPharma Holdings, Inc. announced a second funding tranche and a change in its independent registered accounting firm, alongside disclosures of going concern doubt and material weaknesses.
Aspire Biopharma Holdings, Inc. has entered into a Securities Purchase Agreement to sell convertible promissory notes totaling $9.6875 million in principal for $7.75 million, aiming to repay debt and fund working capital.
Aspire Biopharma Holdings, Inc. has announced significant changes to its executive leadership and Board of Directors, including the immediate resignation of its CEO and two directors, one citing irreconcilable differences.
Aspire Biopharma Holdings, Inc. announced on June 17, 2025, the relocation of its principal executive office, principal place of business, and headquarters to Estero, Florida.
Aspire Biopharma Holdings, Inc. announced the appointment of Michael C. Howe, a seasoned executive with over four decades of experience in healthcare and consumer brands, as its new Chief Executive Officer, effective June 10, 2025, with former CEO Kraig Higginson transitioning to Executive Chairman.
Aspire Biopharma Holdings, Inc. settles with lenders, resolving default notices and extending maturity dates on key promissory notes.
Aspire Biopharma Holdings, Inc. received notices from Nasdaq regarding non-compliance with minimum market value and share price requirements, potentially leading to delisting.
Aspire Biopharma Holdings issues senior secured convertible debentures for $3 million to bolster working capital and operating expenses.
Aspire Biopharma begins trading on Nasdaq under the ticker ASBP following the completion of its business combination with PowerUp Acquisition Corp., aiming to develop innovative drug delivery mechanisms.
PowerUp Acquisition Corp. announces shareholder approval of its business combination with Aspire Biopharma at an extraordinary general meeting held on February 4, 2025.